» Articles » PMID: 11773288

Traditional and Newer Pathologic Factors

Overview
Specialty Oncology
Date 2002 Jan 5
PMID 11773288
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

There has long been a pressing clinical need to identify prognostic and predictive factors for patients with breast cancer. Although numerous candidate biological and molecular markers have been identified during the last two decades, traditional factors such as lymph node status, tumor size, histologic type, histologic grade, and hormone receptor status remain the most useful indicators of prognosis and therapeutic response. A major obstacle to the translation of research advances into clinically useful prognostic and predictive markers has been the considerable methodologic variability used in the evaluation of the newer markers. It is now generally accepted that, to be useful in patient management, a putative prognostic or predictive marker must have clinical importance, independence, significance, and standardization with regard to methods, interpretation, and reporting. It is hoped that recognition and adoption of these criteria will serve to clarify the value of newer biologic and molecular markers.

Citing Articles

Prognostic Significance of Transverse Relaxation Rate (R2*) in Blood Oxygenation Level-Dependent Magnetic Resonance Imaging in Patients with Invasive Breast Cancer.

Choi H, Ko E, Han B, Kim E, Kim S, Lim Y PLoS One. 2016; 11(7):e0158500.

PMID: 27384310 PMC: 4934782. DOI: 10.1371/journal.pone.0158500.


Individualized Survival and Treatment Response Predictions in Breast Cancer Patients: Involvements of Phospho-EGFR and Phospho-Her2/neu Proteins.

Guo L, Abraham J, Flynn D, Castranova V, Shi X, Qian Y Open Clin Cancer J. 2015; 2:18-31.

PMID: 25558292 PMC: 4282131. DOI: 10.2174/1874189400802010018.


The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer.

Mohammed Z, McMillan D, Edwards J, Mallon E, Doughty J, Orange C BMC Clin Pathol. 2013; 13(1):31.

PMID: 24274633 PMC: 4175483. DOI: 10.1186/1472-6890-13-31.


Statistical consideration for clinical biomarker research in bladder cancer.

Shariat S, Lotan Y, Vickers A, Karakiewicz P, Schmitz-Drager B, Goebell P Urol Oncol. 2010; 28(4):389-400.

PMID: 20610277 PMC: 3407571. DOI: 10.1016/j.urolonc.2010.02.011.


A population-based gene signature is predictive of breast cancer survival and chemoresponse.

Rathnagiriswaran S, Wan Y, Abraham J, Castranova V, Qian Y, Guo N Int J Oncol. 2010; 36(3):607-16.

PMID: 20126981 PMC: 3103999. DOI: 10.3892/ijo_00000536.